Ascendis Health

ASCENDIS HEALTH APPOINTS THOMAS THOMSEN AS NEW CHIEF EXECUTIVE

Johannesburg – JSE-listed health and care group Ascendis Health today announced the appointment of Thomas Thomsen as chief executive officer with effect from 1 March 2018.

MEDIA RELEASE 27 February 2018

Johannesburg – JSE-listed health and care group Ascendis Health today announced the appointment of Thomas Thomsen as chief executive officer with effect from 1 March 2018.

London-based Thomsen (48) is currently the chief operating officer of Ascendis.

He will succeed Dr Karsten Wellner (57) who has been the CEO of Ascendis since the founding of the group in 2011. Karsten will stand down as CEO on 1 March and as an executive director of Ascendis on 30 June 2018.

Ascendis chairman John Bester said: “The board believes it is the right time to hand over to new leadership, with extensive operational and management experience in the global consumer healthcare and pharmaceutical markets, to drive the future strategy of the group.

He said the appointment is part of a phased succession plan initiated when Thomsen was recruited in August 2017. “Thomas has a proven track record in senior executive positions in major global consumer healthcare companies and as a non-executive director of private equity and listed companies,” said Bester.

A Danish national, Thomsen has held senior roles at Johnson & Johnson Consumer (managing director of Central and Eastern Europe, Turkey and Nordic region), Reckitt Benckiser (senior vice president Global Consumer Healthcare) and Novartis Consumer Healthcare (head of Global Category).

Over the past two years Ascendis has transformed into a global healthcare business following the international acquisitions of pharmaceutical manufacturer Remedica in Cyprus, European sports nutrition specialist Scitec (both in 2016) and nutraceuticals business Sun Wave Pharma in Romania (2017). Internationally Ascendis has operations in Spain, Cyprus, Hungary, Romania and Australia, with close to 60% of the group’s earnings being generated internationally.

Bester said Wellner has made an outstanding contribution to the group over the past seven years, “driving and overseeing the growth of Ascendis into a leading multinational health and care company with annualised revenues of approximately R8 billion, exports to over 120 countries and more than 4 000 employees.”

“Thomas and Karsten will work together over the next four months to ensure a smooth transition. We are confident in Thomas’ ability to lead the next stage in the evolution of Ascendis and to continue the growth momentum created by Karsten and the team,” added Bester.

Ends
Issued by Tier 1 Investor Relations on behalf of Ascendis Health
Enquiries
Graeme Lillie, Tier 1 Investor Relations 082 468 1507